Ju Fu Tang Biotech Holdings Co., Ltd released a positive profit alert, indicating an expected net profit attributable to shareholders of approximately HK$23.00 million for the year ended 31 March 2026. This represents a sharp turnaround from the HK$6.00 million loss recorded in FY2025.

Management attributes the swing to two key factors: 1. Fair value gains of about HK$27.00 million from financial assets measured at fair value through profit or loss. 2. A reduction in administrative and other expenses as the Group intensified its cost-control initiatives.

The figures are based on unaudited consolidated management accounts and may be adjusted after review by the Company’s audit committee. Full annual results are scheduled for release on or before the end of June 2026. The Board advised shareholders and potential investors to exercise caution when dealing in the Company’s shares pending the publication of the audited results.